An Observational Study of Herceptin SC Safety in Breast Cancer
- Cancer
- Breast Cancer
Completed
- South Korea
NCT02305628 ML29625
Trial Summary
This is a phase IV, prospective, multicenter, observational study (regulatory post-marketing surveillance) in approximately 600 patients who are to receive Herceptin SC (trastuzumab, subcutaneous administration) per approved local labeling. Patients will be under observation according to standard of care in Korea.
Post-Marketing Surveillance of Herceptin Subcutaneous in Breast Cancer
Eligibility Criteria
- All patients administered Herceptin SC for the locally approved indications
N/A
For the latest version of this information please go to www.forpatients.roche.com